Literature DB >> 30993543

Interaction between phytotherapy and oral anticancer agents: prospective study and literature review.

Anne-Laure Clairet1,2, Marie Boiteux-Jurain1, Elsa Curtit2,3, Marie Jeannin1, Blandine Gérard1, Virginie Nerich4,5, Samuel Limat1,2.   

Abstract

Cancer is becoming more prevalent in elderly patient. Due to polypharmacy, older adults with cancer are predisposed to drug-drug interactions. There is also an increasing interest in the use of complementary and alternative medicine (CAM). Thirty to seventy percent of patients with cancer have used CAM. Through pharmaceutical counseling sessions, we can provide advices on herb-drug interactions (HDI). All the patients seen in pharmaceutical counseling sessions were prospectively included. Information was collected during these sessions: prescribed medication (oral anticancer agents (OAA) and other drugs), CAM (phytotherapy especially), and use of over-the-counter (OTC) drugs. If pharmacist considered an interaction or an intervention clinically relevant, the oncologist was notified. Then, a literature review was realized to identify the potential HDI (no interactions, precautions for use, contraindication). Among 201 pharmacist counseling sessions, it resulted in 104 interventions related to 46 HDI, 28 drug-drug interactions and 30 others (wrong dosage, omission…). To determine HDI, we review 73 medicinal plants which are used by our patients with cancer and 31 OAA. A total of 1829 recommendations were formulated about 59 (75%) medical plants and their interaction with an OAA. Herb-drug interactions should not be ignored by healthcare providers in their management of cancer patients in daily practice.

Entities:  

Keywords:  Herb–drug interactions; Oncology; Oral anticancer agents; Phytotherapy

Mesh:

Substances:

Year:  2019        PMID: 30993543     DOI: 10.1007/s12032-019-1267-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  7 in total

Review 1.  A Concept Analysis of Oral Anticancer Agent Self-management.

Authors:  Madilyn Mason; Marcelline R Harris; Joseph A Greer; Yun Jiang
Journal:  Cancer Nurs       Date:  2022 Mar-Apr 01       Impact factor: 2.592

2.  Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases.

Authors:  F Ranchon; C Rioufol; H Prely; C Herledan; A G Caffin; A Baudouin; V Larbre; M Maire; V Schwiertz; N Vantard
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-29       Impact factor: 4.553

Review 3.  Potential Herb-Drug Interactions in the Management of Age-Related Cognitive Dysfunction.

Authors:  Maria D Auxtero; Susana Chalante; Mário R Abade; Rui Jorge; Ana I Fernandes
Journal:  Pharmaceutics       Date:  2021-01-19       Impact factor: 6.321

4.  UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics.

Authors:  Bo-Wen Wang; Cheng-Zheng Qiu; Chang-Qian Tang; Jia-Hui Zhang; Yi Zhang; Qi-Guang Du; Yi Feng; Xiang-Jun Qiu
Journal:  Biomed Res Int       Date:  2021-02-23       Impact factor: 3.411

Review 5.  Adverse events of targeted therapies approved for women's cancers.

Authors:  Mathilde Saint-Ghislain; Chloé Levenbruck; Audrey Bellesoeur
Journal:  Int J Womens Dermatol       Date:  2021-10-27

6.  Complementary and Integrative Approaches to Cancer: A Pilot Survey of Attitudes and Habits among Cancer Patients in Italy.

Authors:  Massimo Bonucci; Andrea Geraci; Dina Pero; Cristina Villivà; Daniele Cordella; Maria Condello; Stefania Meschini; Laura Del Campo; Franco Tomassi; Alessandro Porcu; Francesco De Lorenzo; Francesco Lozupone
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-01       Impact factor: 2.650

7.  Knowledge and use of complementary therapies in a tertiary care hospital in France: A preliminary study.

Authors:  Mireille Michel-Cherqui; Rebecca Had-Bujon; Aurèlie Mongereau; Caroline Delannoy; Elodie Feliot; Florian Scotté; Marc Fischler
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.